Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.53 USD | -0.92% | -7.83% | -26.96% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on NeuroPace, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering NeuroPace, Inc.
Morgan Stanley | |
Wells Fargo Securities | |
JPMorgan Chase | |
Leerink Partners | |
Cantor Fitzgerald | |
Lake Street | |
Wolfe Research | |
SVB Leerink | |
Baird | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- NPCE Stock
- Consensus NeuroPace, Inc.